Dr. Benjamin Derman and Dr. Manni Mohyuddin discuss updates in Minimal Residual Disease (MRD) in multiple myeloma, including the potential use of MRD as a surrogate endpoint for accelerated FDA approval. They explore the benefits and challenges of achieving MRD negativity, advancements in MRD detection technologies, implications of MRD resurgence, and the impact of MRD negativity on treatment decisions and discontinuation. The podcast sheds light on the complexities of utilizing MRD in myeloma treatment strategies.

Experts Dr. Hira Mian and Dr. Manni Mohyuddin discuss maintenance therapy in multiple myeloma, exploring studies like Meta-analysis of CALGB, Myeloma XI RCT, Canadian real-world data, and more. They analyze trials like FORTE and ATLAS, debating options for high-risk patients and emphasizing personalized treatment approaches.